[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Park YM, Cho JH, Cho JY, Huh JS, Ahn JY: Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy. World J Surg Oncol; 2007;5:86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy.
  • BACKGROUND: Solitary involvement of the sphenoid sinus has rarely been reported in non-Hodgkin's lymphoma.
  • Isolated oculomotor nerve palsy is uncommon as an initial presentation of malignant tumors of the sphenoid sinus.
  • Magnetic Resonance Imaging (MRI) demonstrated a homogenous soft-tissue lesion occupying the left sphenoid sinus and invading the left cavernous sinus.
  • The patient underwent transsphenoidal biopsy and the lesion was histologically diagnosed as non-Hodgkin's lymphoma, diffuse large B-cell type.
  • Tumor cells were positive for CD20 and negative for CD3.
  • Following six cycles of chemotherapy, the left oculomotor nerve palsy that had been previously observed was completely resolved.
  • CONCLUSION: It is important to recognize that non-Hodgkin's lymphoma of the sphenoid sinus can present with isolated oculomotor nerve palsy, although it is extremely rare.
  • The cranial nerve deficits can resolve dramatically after chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Oculomotor Nerve Diseases / etiology. Paranasal Sinus Neoplasms / complications. Sphenoid Sinus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurochirurgie. 2002 Dec;48(6):522-6 [12595809.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Acta Neurol Belg. 2000 Jun;100(2):103-6 [10934562.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Am J Ophthalmol. 2000 Feb;129(2):256-8 [10682985.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):299-306 [16163447.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 May;120(5):730-6 [10229601.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Radiology. 1997 Aug;204(2):431-5 [9240531.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1995;112(6):298-302 [8561414.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1281-91 [7882278.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Apr;102(4 Pt 1):318-21 [8476174.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] No Shinkei Geka. 1992 Mar;20(3):283-7 [1557180.001]
  • [Cites] Radiology. 1988 Jun;167(3):803-8 [3363145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Am J Clin Pathol. 1984 Jun;81(6):721-7 [6547270.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1925-31 [7427898.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer Treat Rev. 2003 Feb;29(1):11-9 [12633576.001]
  • [Cites] Cancer. 1978 Aug;42(2):406-16 [679145.001]
  • (PMID = 17683562.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950883
  • [General-notes] NLM/ Original DateCompleted: 20070828
  •  go-up   go-down


2. Lin HF, Lui CC, Hsu HC, Lin SA: Orbital exenteration for secondary orbital tumors: a series of seven cases. Chang Gung Med J; 2002 Sep;25(9):599-605

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exenteration is indicated in patients with malignant neoplasms of orbital contents.
  • It entails the removal of the eyeball together with its extraocular muscles and other soft tissues.
  • Primary lesions, histopathological examination results, treatments, and recurrences are discussed.
  • RESULTS: Classification of the 7 patients showed that 2 had basal cell carcinoma of the skin, 2 had squamous cell carcinoma of the conjunctiva, 1 had squamous cell carcinoma of the paranasal sinus, 1 had rhabdomyosarcoma of the paranasal sinus, and 1 had intracranial meningioma.
  • Radiotherapy was performed in 6 of the patients and chemotherapy in 2.
  • CONCLUSION: Secondary orbital tumors involved the orbit from adjacent tissues: paranasal sinuses, nasopharynx, lacrimal sac, conjunctiva, eyelid, intraocular tissue, and intracranial tissues.
  • Combined surgeries are necessary for complete tumor removal.
  • And the imaging studies should include the field of the orbit, sinus, and brain to search for the primary lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479621.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


3. Nagano H, Yoshifuku K, Deguchi K, Kurono Y: Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report. Auris Nasus Larynx; 2010 Apr;37(2):238-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report.
  • Malignant tumors in the paranasal sinuses and nasal cavity are mostly squamous cell carcinomas, with comparatively few adenocarcinomas.
  • Adenocarcinoma developing in paranasal sinuses and nasal cavity generally has a low response to radiotherapy and low chemotherapeutic sensitivity, making surgery the most reliable treatment.
  • We report the case of a 62-year-old man who presented with nasal congestion and epistaxis.
  • We were unable to observe an oncogenic lesion in the nasal cavity directly, but the tumor gave inhomogeneous low intensity signals on T1-weighted images and an isointense signal on T2-weighted images in MRI.
  • Six courses of chemotherapy by super-selective intra-arterial infusion of cisplatin with concurrent intensity-modulated radiation therapy of 70Gy were performed at another hospital.
  • However, the tumor enlarged and developed distant metastasis to the lung after this therapy.
  • Therefore, TPF chemotherapy (docetaxel, cisplatin and 5-fluorouracil) was performed 5 times, after which the tumor gradually reduced in size.
  • The patient is alive after a follow-up period of 43 months, indicating that TPF chemotherapy may be useful for adenocarcinoma of the paranasal sinuses and nasal cavity.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Nose Neoplasms / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19560300.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. García González LA, Redondo Ventura F: [Metastases in both internal auditive meatus of nasosinusal melanoma]. An Otorrinolaringol Ibero Am; 2005;32(6):537-44
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Metastasis en ambos conductos auditivos internos de melanoma nasosinusal. A propósito de un caso.
  • Primary malignant melanoma of the nasal and paranasal sinusses is rare and represent 3% of malignant nasosinusal tumors.
  • The prognosis of this tumor is poor.
  • Chemotherapy is used for metastatic forms.
  • We present a case of a patient with a primary malignant melanoma of the nasal mucosa.
  • Tree years after diagnosis we found intracranial metastases in left and right auditive internal meatus.
  • [MeSH-major] Ear Neoplasms / secondary. Ear, Inner / pathology. Melanoma / secondary. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475540.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Nitsche M, Hermann RM, Christiansen H, Berger J, Pradier O: Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report. Onkologie; 2005 Dec;28(12):653-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report.
  • BACKGROUND: Sinonasal Teratocarcinosarcoma (SNTC) is a very unusual and aggressive neoplasm characterized by the combination of malignant teratoma and carcinosarcoma features.
  • We present the first case of malignant SNTC treated with individualized multimodal therapy including a histology-specific chemotherapy.
  • Adjuvant chemotherapy with cisplatin, etoposid and ifosfamid were given in regard to the major components of this heterogeneous tumor.
  • Radiotherapy up to 59.4 Gy was applied.
  • CONCLUSION: 36 months after the end of therapy, there is no sign of tumor recurrence or metastasis in our patient.
  • We suggest that surgery, radiotherapy and a histology-specific multidrug chemotherapy seems to be a therapeutic approach that is appropriate for this heterogeneous tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / therapy. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy. Teratocarcinoma / therapy
  • [MeSH-minor] Adult. Cisplatin / therapeutic use. Combined Modality Therapy. Etoposide / therapeutic use. Fluorouracil / therapeutic use. General Surgery. Humans. Ifosfamide / therapeutic use. Male. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330889.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Unal A, Ozlugedik S, Tezer MS, Kulacoglu S, Ozcan M: An atypical esthesioneuroblastoma of the inferior nasal cavity and maxillary sinus: report of a case. Tumori; 2006 Sep-Oct;92(5):440-3
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical esthesioneuroblastoma of the inferior nasal cavity and maxillary sinus: report of a case.
  • Esthesioneuroblastoma is a rare malignant tumor of the nasal cavity that originates from the olfactory epithelium.
  • In this paper a very rare clinical presentation of this tumor is described.
  • The tumor originated from the maxillary sinus and alveolar process, and was independent of the olfactory region.
  • The patient was a 14-year-old girl presenting with facial swelling and nasal obstruction.
  • Paranasal computed tomography showed a mass filling the right nasal cavity, infiltrating the alveolar process, eroding the anterior wall of the maxilla and invading the subcutaneous tissues of the cheek.
  • After neoadjuvant chemotherapy, we performed a right subtotal and left inferior maxillectomy and reconstructed the maxillary defect with a permanent obturator.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Maxillary Sinus Neoplasms. Nasal Cavity. Nose Neoplasms
  • [MeSH-minor] Adolescent. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168440.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


7. Prasad ML, Busam KJ, Patel SG, Hoshaw-Woodard S, Shah JP, Huvos AG: Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract. Arch Pathol Lab Med; 2003 Aug;127(8):997-1002
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic differences in malignant melanoma arising in oral squamous and sinonasal respiratory mucosa of the upper aerodigestive tract.
  • We compare melanomas arising in 2 histologically different mucosa, the stratified oral squamous mucosa and pseudostratified sinonasal respiratory mucosa, to investigate the clinicopathologic influence of native mucosal histology on the tumor.
  • Sinonasal melanoma showed vascular and deep tissue invasion more frequently than oral melanoma; however, no significant difference in disease-specific survival was noted (median survival, 2.8 years vs 3.0 years; 5-year survival, 37% vs 35%, respectively).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Melanoma / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology. Nose Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Nasal Mucosa / drug effects. Nasal Mucosa / pathology. Nasal Mucosa / surgery. Neoplasm Invasiveness / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery


8. Peng RQ, Wu GH, Chen WK, Ding Y, Ma J, Zhang NH, Su YS, Zhang XS: [Clinical characteristics and prognosis of primary nasal mucosal melanoma--a report of 44 cases]. Ai Zheng; 2006 Oct;25(10):1284-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognosis of primary nasal mucosal melanoma--a report of 44 cases].
  • BACKGROUND & OBJECTIVE: Primary mucosal malignant melanoma of the nasal cavity, paranasal sinuses, and nasopharynx is rare and current research data of this disease are mainly from western populations.
  • 2005, 66 patients with primary nasal mucosal melanoma were treated in Cancer Center of Sun Yat-sen University, China.
  • Demographics and baseline characteristics, treatments, recurrence, metastasis, and survival were documented in hospital records.
  • RESULTS: Among 44 evaluable cases, 37 were originated from the nasal cavity, 5 from the paranasal sinuses, and 2 from the nasopharynx.
  • Of the 31 patients received operation-dominated treatment, 8 received adjuvant radiotherapy, 13 received adjuvant chemotherapy, and 6 received adjuvant non-specific immunotherapy.
  • The median time of follow-up was 29 months.
  • The median survival time was 24 months and the 5-year survival time was 25%.
  • Clinical stage affected prognosis, whereas age, gender, site, primary tumor mass, and adjuvant therapy were not correlated to survival status.
  • CONCLUSION: Nasal mucosal melanoma has high incidence of local recurrence and distant metastasis, especially cervical lymphadenopathy.
  • [MeSH-major] Melanoma. Nasal Mucosa. Neoplasm Recurrence, Local. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Nasal Cavity. Neoplasm Staging. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059777.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


9. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina Dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck; 2005 Jul;27(7):575-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study.
  • BACKGROUND: Malignant tumors of the superior sinonasal vault are rare, and, because of this and the varied histologic findings, most outcomes data reflect the experience of small patient cohorts.
  • This International Collaborative study examines a large cohort of patients accumulated from multiple institutions experienced in craniofacial surgery, with the aim of reporting benchmark figures for outcomes and identifying patient-related and tumor-related predictors of prognosis after craniofacial resection (CFR).
  • One hundred eighty-eight patients (56.3%) had had prior single-modality or combined treatment, which included surgery in 120 (36%), radiation in 79 (23.7%), and chemotherapy in 56 (16.8%).
  • Adjuvant radiotherapy was given in 161 (48.2%) and chemotherapy in 16 (4.8%).
  • Statistical analyses for outcomes were performed in relation to patient characteristics, tumor characteristics, including histologic findings and extent of disease, surgical resection margins, prior radiation, and prior chemotherapy to determine predictive factors.
  • The status of surgical margins, histologic findings of the primary tumor, and intracranial extent were independent predictors of overall, disease-specific, and recurrence-free survival on multivariate analysis.
  • CONCLUSIONS: CFR for malignant paranasal sinus tumors is a safe surgical treatment with an overall mortality of 4.5% and complication rate of 33%.
  • The status of surgical margins, histologic findings of the primary tumor, and intracranial extent are independent predictors of outcome.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Paranasal Sinus Neoplasms / surgery. Skull / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Postoperative Complications. Skull Base / pathology. Skull Base / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825201.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


10. Preś K, Pośpiech L, Krecicki T, Nadolska B, Kubacka M, Zatoński T, Jabłonka A, Piechnik-Resler D, Jankowska-Konsur A: [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001]. Wiad Lek; 2006;59(11-12):797-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001].
  • Malignant neoplasms of the nose and paranasal sinuses occur rarely but due to late diagnosis and poor treatment effects still remain a serious problem.
  • The aim of the study was the analysis of all nose and paranasal sinus neoplasms treated at Lower Silesia in the years 1992-2001.
  • MATERIAL AND METHODS: In the years 1992-2001 in Lower Silesia region there were 182 patients treated for malignant nose and paranasal sinus tumors.
  • Principal management was combined therapy--surgery with radiotherapy in 84% of the cases.
  • Radiotherapy alone was performed in 8.8% and chemotherapy as palliative treatment in 7.1%.
  • Most of the tumors (57%) arose from middle segment of ethmomaxillary sinuses.
  • CONCLUSIONS: Unsatisfactory results of treatment are an effect of a high advanced stage of the tumor while diagnosed.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Nose Neoplasms / epidemiology. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging / classification. Nose. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427494.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Knott PD, Gannon FH, Thompson LD: Mesenchymal chondrosarcoma of the sinonasal tract: a clinicopathological study of 13 cases with a review of the literature. Laryngoscope; 2003 May;113(5):783-90
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Mesenchymal chondrosarcoma of the sinonasal tract is a rare, malignant tumor of extraskeletal origin.
  • RESULTS: Nine women and 4 men (age range, 11 to 83 y; mean age, 38.8 y) presented with nasal obstruction (n = 8), epistaxis (n = 7), or mass effect (n = 4), or a combination of these.
  • The maxillary sinus was the most common site of involvement (n = 9), followed by the ethmoid sinuses (n = 7) and the nasal cavity (n = 5).
  • All cases were managed by surgery with adjuvant radiation therapy (n = 4) and/or chemotherapy (n = 3).
  • The overall mean survival was 12.1 years, although five of six patients who developed local recurrences died of disease (mean survival, 6.5 y).
  • CONCLUSIONS: Mesenchymal chondrosarcoma of the sinonasal tract is an aggressive tumor with a predilection for young women.
  • Aggressive, exenterative surgery combined with adjuvant therapy appears to yield the best clinical outcome.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Chondrosarcoma, Mesenchymal / radiography. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / radiography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792311.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


12. DeMonte F, Ginsberg LE, Clayman GL: Primary malignant tumors of the sphenoidal sinus. Neurosurgery; 2000 May;46(5):1084-91; discussion 1091-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant tumors of the sphenoidal sinus.
  • OBJECTIVE: Neoplasms of the paranasal sinuses account for 0.2 to 0.8% of all cancers and for 2 to 3% of head and neck cancers.
  • Primary involvement of the sphenoidal sinus has been reported to occur in only 1 to 2% of all paranasal sinus tumors.
  • Tumors at this site commonly present with cranial neuropathies and require multidisciplinary treatment.
  • METHODS: During a 21-year period, 27 patients with primary sphenoidal sinus tumors were evaluated.
  • The records of all remaining patients were reviewed for the following parameters: age, sex, and ethnic origin; presenting symptoms and signs; radiological features and sites of tumor extension; pathological findings; prior treatments; surgical approaches and extent of resection; adjuvant therapy; complications; and patient outcome.
  • RESULTS: A malignant pathological process was found in 26 of the 27 patients.
  • Treatments included surgery (n = 1), surgery and radiotherapy (n = 6), surgery and chemotherapy (n = 3), surgery, radiotherapy, and chemotherapy (n = 4), chemotherapy (n = 5), chemotherapy and radiotherapy (n = 3), and radiotherapy (n = 2).
  • CONCLUSION: Headache and visual disturbances are common symptoms of sphenoidal sinus tumors.
  • It is advantageous if the surgical team has had experience with both open and endoscopic approaches to the sphenoidal sinus.
  • Patient outcome is maximized by the use of aggressive multidisciplinary therapy.
  • [MeSH-major] Paranasal Sinus Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Chondrosarcoma / diagnosis. Chondrosarcoma / mortality. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Combined Modality Therapy. Endoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807240.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Mrówka-Kata K, Namysłowski G, Scierski W, Fira R, Lange D: [The rare case of sinonasal osteosarcoma in a 22-year-old patient (case report)]. Pol Merkur Lekarski; 2005 Sep;19(111):432-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcomas of head and neck are very rare and comprise about 10 to 15% of all malignant nonepithelial neoplasms.
  • The preoperative symptoms, histological character of the tumor and postoperative status were shown and discussed.
  • Patient was treated by combined method: the surgical excision and radio-chemotherapy.
  • [MeSH-major] Osteosarcoma. Paranasal Sinus Neoplasms
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358898.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Abada RL, Kadiri F, Tawfik N, Benchakroun N, Bouchbika Z, Chekkoury AI, Benchakroun Y, Benider A: [Multiple metastases of a mandibular ameloblastoma]. Rev Stomatol Chir Maxillofac; 2005 Jun;106(3):177-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ameloblastoma is a benign odontogenic tumor which can be locally aggressive and invasive.
  • Metastases are rare but possible and must be considered as a malignant form of the tumor.
  • OBSERVATION: A 50-year-old woman presented a jugal metastasis of a mandibular ameloblastom which had been treated several times 28 years earlier.
  • Six months after resection of the metastasis, the patient developed multiple cervical node metastases which were removed by radical curettage.
  • Five months later, new metastases developed on the scalp and three months later a voluminous metastasis involving the right hemiface extended to the base of the skull.
  • DISCUSSION: The absence of any histological sign of malignity in the primary tumor and in the metastases, as observed in our patient, is remarkable.
  • The time to development of a metastasis is generally very long and metastases usually remain asymptomatic.
  • Progression is very slow, like for the primary tumor.
  • Several factors predictive of metastasis have been described: female gender, age at onset of primary tumor (2nd to 3rd decade) and multiple local recurrences.
  • There is no standard treatment for metastases.
  • Chemotherapy is not effective.
  • Surgical resection remains the treatment of choice.
  • [MeSH-minor] Female. Follow-Up Studies. Head and Neck Neoplasms / secondary. Humans. Lymphatic Metastasis / pathology. Middle Aged. Paranasal Sinus Neoplasms / secondary. Scalp / pathology. Skin Neoplasms / secondary. Skull Neoplasms / secondary. Zygoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976707.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the oncologic outcomes of patients with sinonasal cancer treated with endoscopic resection.
  • SETTING: Tertiary care academic cancer center.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • CONCLUSIONS: To the best of our knowledge, this is the largest US series to date of patients with malignant tumors of the sinonasal tract treated with endoscopic resection.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Vedrine PO, Thariat J, Merrot O, Percodani J, Dufour X, Choussy O, Toussaint B, Dassonville O, Klossek JM, Santini J, Jankowski R: Primary cancer of the sphenoid sinus--a GETTEC study. Head Neck; 2009 Mar;31(3):388-97
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancer of the sphenoid sinus--a GETTEC study.
  • BACKGROUND: Primary involvement of the sphenoid sinus occurs in 2% of all paranasal sinus tumors and is associated with dismal prognosis.
  • METHODS: A total of 23 patients were treated for a primary cancer of the sphenoid sinus from 1988 to 2004.
  • Charts were reviewed for patient-, tumor-, and treatment-related parameters.
  • Pathologic findings included adenoid cystic carcinoma, adenocarcinoma, lymphoma, squamous cell carcinoma, sarcoma, neuroendocrine carcinoma, melanoma, and malignant hemangiopericytoma.
  • All but 2 patients had stages III to IV cancer.
  • Radiotherapy was performed in 18 patients and chemotherapy in 12.
  • Surgery was rarely complete because of advanced stages at presentation, but it yielded better outcomes than other treatments without surgery in non lymphoma-cases.
  • Surgery, including debulking surgery, may be preferred to combined modality treatments without surgery.
  • Highly conformal radiotherapy (adjuvant or definitive) should be encouraged and optimized with concurrent chemotherapy in advanced stages.
  • Aggressive multidisciplinary management including surgery, chemotherapy, and radiotherapy should be encouraged and adapted on histology and tumor extensions.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / therapy. Chemotherapy, Adjuvant. Cranial Nerve Diseases / complications. Diagnostic Imaging. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / therapy. Meningioma / mortality. Meningioma / pathology. Meningioma / therapy. Middle Aged. Multivariate Analysis. Plasmacytoma / mortality. Plasmacytoma / pathology. Plasmacytoma / therapy. Preoperative Care. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972425.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


17. Jurkiewicz D, Wojdas A, Hermanowski M: [Malignant tumors of the nose and paranasal sinuses in the years 1971-2005 in the material of the Otolaryngology Clinic WIM]. Otolaryngol Pol; 2007;61(4):572-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the nose and paranasal sinuses in the years 1971-2005 in the material of the Otolaryngology Clinic WIM].
  • The aim of this study was retrospective analysis of evidence concerning to malignant tumors of the nasal cavity and the paranasal sinuses diagnosed in Otolaryngology Clinic of the Military Institute of the Health Service 1971-2005.
  • The methods of therapy were also discussed.
  • MATERIAL AND METHODS: Material comprised 113 patients (35 females and 78 males) with diagnosis of malignant tumors of the nose and paranasal sinuses.
  • The clinical aspects, sex, age, TNM classification and therapy methods (surgery, radiotherapy, chemotherapy) were analysed.
  • In 89 subjects (23 females and 66 males) the neoplasm of epithelial origin were diagnosed.
  • Three of patients did not agree for therapy.
  • CONCLUSIONS: The most frequent of malignant tumors of the nose and paranasal sinuses was cancer.
  • The clinical symptoms of tumor were disclosed most often in age of 60-80 years.
  • The method of choice in treatment is surgery combined with postoperative radiation.
  • [MeSH-major] Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260254.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Enepekides DJ: Sinonasal undifferentiated carcinoma: an update. Curr Opin Otolaryngol Head Neck Surg; 2005 Aug;13(4):222-5
Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Sinonasal undifferentiated carcinoma is a rare and extremely malignant tumor of the paranasal sinuses.
  • Historically, treatment outcomes have been poor.
  • This review presents recent data on the management of sinonasal undifferentiated carcinoma and examines treatment trends that may result in improved locoregional control and survival.
  • RECENT FINDINGS: Patients who receive aggressive multimodality treatments have improved outcomes.
  • In particular, a chemoradiotherapy regimen including concurrent platinum-based chemotherapy given preoperatively or postoperatively to patients with resectable disease seems to result in better disease-free survival.
  • Neoadjuvant chemotherapy, although strongly advocated by some, is currently not offered by many.
  • Although surgery seems to be an important part of the treatment for sinonasal undifferentiated carcinoma, its ideal timing, either upfront or after radiotherapy, remains uncertain.
  • An aggressive approach using surgery, platinum-based chemotherapy, and radiation seems to offer the greatest chance for significant locoregional control and survival.
  • [MeSH-major] Carcinoma / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Immunohistochemistry. Keratins / metabolism. Neoplasm Invasiveness. Prognosis. Radiotherapy, Adjuvant. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012246.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


19. Ejaz A, Wenig BM: Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol; 2005 May;12(3):134-43
Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis.
  • SNUC typically presents as a rapidly enlarging tumor mass involving multiple (sinonasal tract) sites, often with evidence of extension beyond the anatomic confines of the sinonasal tract.
  • The tumor cells are medium to large sized and round to oval and have pleomorphic and hyperchromatic nuclei, inconspicuous to prominent nucleoli, varying amount of eosinophilic cytoplasm, high nuclear-to-cytoplasmic ratio, marked increase in mitotic activity frequently with atypical mitoses, tumor necrosis, and apoptosis.
  • Adjunct analyses (eg, immunohistochemistry, electron microscopy, and molecular biologic studies) are often required in the diagnosis of SNUC and in differentiating it from other undifferentiated malignant neoplasms.
  • The treatment of SNUC includes aggressive multimodality therapy, including surgical resection and adjuvant therapy (ie, radiotherapy, chemotherapy).
  • The prognosis associated with SNUC is poor, and death due to disease often occurs within short periods following the diagnosis.
  • Irrespective of its cell of origin and perhaps even in the face of differentiated foci in limited parts of the tumor, given its rather unique clinicopathologic characteristics, this tumor should be identified and classified as SNUC, thereby differentiating it from the other specific types of sinonasal carcinomas and nonepithelial malignant tumors.
  • [MeSH-major] Carcinoma / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Neuroendocrine / pathology. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / pathology. Humans. Lymphoma, T-Cell, Cutaneous / pathology. Male. Melanoma / pathology. Middle Aged. Nasal Cavity / pathology. Nose Neoplasms / pathology. Prognosis. Rhabdomyosarcoma / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900114.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


20. Iguchi Y, Takahashi H, Yao K, Nakayama M, Nagai H, Okamoto M: Malignant fibrous histiocytoma of the nasal cavity and paranasal sinuses: review of the last 30 years. Acta Otolaryngol Suppl; 2002;(547):75-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the nasal cavity and paranasal sinuses: review of the last 30 years.
  • The clinical and pathologic features of four patients with malignant fibrous histiocytoma of the maxillary sinus were studied.
  • All patients were male, with an age range of 43-71 years at the time of diagnosis.
  • The main symptoms were pain in the facial region, swelling of the cheek and nasal bleeding.
  • Pathologically, three patients were subclassified with the striform-pleomorphic type of malignant fibrous histiocytoma and one with the myxoid type.
  • All patients were operated on and received various combinations of pre- and postoperative irradiation and intra-arterial chemotherapy given via the temporal artery.
  • In the patient with the best prognosis, tumor extension within the maxillary sinus was minimal.
  • Two patients developed local recurrences and died.
  • None of the patients developed locoregional lymph node or systemic metastases.
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / therapy. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Male. Middle Aged. Nasal Cavity / pathology. Nasal Cavity / radiography. Nasal Cavity / surgery. Outcome Assessment (Health Care). Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212601.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 13
  •  go-up   go-down


21. Issing PR, Hemmanouil I, Wilkens L, Karstens H, Lenarz T: [Long term results in adenoidcystic carcinoma]. Laryngorhinootologie; 2002 Feb;81(2):98-105
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Langzeitergebnisse beim adenoidzystischen Karzinom.
  • The exact distribution of the ACC was: parotid gland (n = 18), submandibular gland (n = 8), oral cavity (n = 10), paranasal sinuses (n = 11), nasopharynx (n = 4) and larynx (n = 3).
  • The most common symptoms were a tumor-related swelling and pain which persisted for a duration of several months after final diagnosis could be established.
  • No definitive differentiation was possible in 10 specimens.
  • Except one patient all 54 underwent surgical therapy.
  • Postoperative radiotherapy was additionally given in 25 cases which was combined with a chemotherapy in 6 patients.
  • Lymphnode metastases were observed in 13 patients after a latency of 3.3 years in average, but predominantly pulmonary metastases as distant spread developed in 18 patients after 5.8 years significantly later.
  • CONCLUSIONS: Due to the uncommon biological behaviour with a slow growth on the one hand side and an aggressive local invasion on the other hand side the ACC can be regarded as a challenging malignant disease for the clinician whose adequate therapy does not allow any standardized regime.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Mouth Neoplasms. Otorhinolaryngologic Neoplasms. Paranasal Sinus Neoplasms. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / surgery. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local. Parotid Neoplasms / diagnosis. Parotid Neoplasms / surgery. Parotid Neoplasms / therapy. Prognosis. Retrospective Studies. Submandibular Gland. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11914946.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Wei-wei L, Qiu-liang W, Guo-hao W, Zhi-hua C, Zong-yuan Z: Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer. Laryngoscope; 2005 Sep;115(9):1574-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer.
  • OBJECTIVES: Postirradiation osteosarcoma (PIOS) arising after radiation of nasopharyngeal cancer (NPC) is rare and seldom reported.
  • Their clinical records, image and pathologic slides, and follow-up data after treatment were collected to perform analysis.
  • The latent time of PIOS after irradiation for NPC ranged from 4 to 27 years, with a mean of 13.3 years.
  • The location where PIOS arose included 33.3% (5/15) from maxilla, 46.7% (7/15) from mandible, and 20% (3/15) from a mixture of nasal cavity and paranasal sinuses.
  • Radiologically, soft tissue mass, bone destruction, and tumor new bone formation were the main characteristics.
  • Pathologic subtypes included 53.3% (8/15) of fibroblastic osteosarcoma, 33.3% (5/15) of chondroblastic osteosarcoma, and 13.3% (2/15) of mixed type osteosarcoma.
  • For 12 patients who had undertaken ablative surgery, 1 patient had residual tumor, and 6 patients had tumor recurrence.
  • The survival time after treatment for all patients ranged from 7 to 41 months, with a mean of 18 months.
  • Statistical analysis showed that sex and tumor bone formation are significant prognostic factors.
  • CONCLUSIONS: PIOS in NPC is a highly malignant disease with poorer prognosis than in other sites.
  • Surgery combined with pre- and postoperative chemotherapy might be an effective way to improve survival.
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology. Middle Aged. Nasal Cavity. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148697.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Khademi B, Moradi A, Hoseini S, Mohammadianpanah M: Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis. Oral Maxillofac Surg; 2009 Dec;13(4):191-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis.
  • BACKGROUND: The present study aimed to report the characteristics, prognostic factors, and treatment outcomes of 71 cases of malignant neoplasms of the sinonasal tract and literature review and analysis of major report series.
  • METHODS: Seventy-one consecutive patients diagnosed with primary malignant neoplasm of the sinonasal tract that were treated and followed up at a university hospital between May 2000 and March 2008 were selected for the present study.
  • Thirty-four patients were treated with surgery followed by a combination of chemotherapy and radiotherapy, 15 with surgery alone, 14 with combined radiotherapy and chemotherapy, six with radiotherapy alone, and two with surgery followed by radiotherapy.
  • In all, we found 42 major series including 8,164 patients with malignant neoplasms of the sinonasal tract.
  • RESULTS: There were 35 women and 36 men ranging in age from 5 to 80 years, with a median age of 55 years at diagnosis.
  • The primary sites included were paranasal sinuses in 51 and nasal cavity in 20.
  • Local recurrence was the most frequent treatment failure.
  • On univariate analysis, cervical lymph nodes involvement, primary tumor size, histologic type, response to therapy, and stage of disease were independent prognostic factors for overall survival.
  • Epithelial tumors consisted of 69% of all malignant neoplasms of sinonasal tract and stages III and IV disease constituted 74.7% of all stages.
  • Local recurrence was the dominant treatment failure in nearly all series.
  • CONCLUSIONS: In this review and by analyzing the large data collection of recent major reported series, we found that malignant neoplasms of the sinonasal tract tend to present at locally advanced stage, with a high frequency of local failure and a moderate to poor outcome.
  • More effective local treatment for improving the local control and overall survival is needed.
  • [MeSH-major] Carcinoma / pathology. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cisplatin / therapeutic use. Cobalt Radioisotopes / therapeutic use. Disease-Free Survival. Female. Fluorouracil / therapeutic use. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiography. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Med Assoc. 2007 Dec;99(12):1407-10 [18229778.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck. 1998 Mar;20(2):97-105 [9484939.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Am J Rhinol. 1999 Mar-Apr;13(2):117-23 [10219440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1042-50 [17570610.001]
  • [Cites] Acta Oncol. 1997;36(1):45-50 [9090965.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):141-7 [17459609.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1992 Mar;14(2):135-7 [1618083.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702 [17161557.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):117-21 [15946555.001]
  • [Cites] J Laryngol Otol. 1980 Mar;94(3):301-9 [7373133.001]
  • [Cites] Otolaryngol Pol. 2008;62(4):436-41 [18837219.001]
  • [Cites] HNO. 2005 Nov;53(11):957-65 [15883842.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Feb;135(2):173-9 [19221246.001]
  • [Cites] Wiad Lek. 2006;59(11-12):797-800 [17427494.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Apr;122(4):499-508 [10740168.001]
  • [Cites] Tumori. 1986 Dec 31;72(6):589-95 [3810867.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Acta Oncol. 1997;36(1):27-31 [9090960.001]
  • [Cites] Laryngoscope. 2009 May;119(5):899-906 [19358246.001]
  • [Cites] Radiol Med. 1994 Sep;88(3):291-4 [7938737.001]
  • [Cites] J Laryngol Otol. 2007 Jan;121(1):49-56 [16995961.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):242-58; quiz 261-2, 264 [16020425.001]
  • [Cites] Laryngorhinootologie. 1991 Mar;70(3):138-41 [2036148.001]
  • [Cites] Acta Radiol Oncol. 1984;23(2-3):181-7 [6331089.001]
  • [Cites] Zhonghua Er Bi Yan Hou Ke Za Zhi. 2000 Jun;35(3):168-71 [12768768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1343-51 [18963535.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Otolaryngol Pol. 2000;54(1):13-5 [10822961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32 [18755554.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2006 Jun;123(3):115-9 [16840900.001]
  • [Cites] Jpn J Clin Oncol. 1995 Oct;25(5):188-94 [7474406.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):27-35 [10924968.001]
  • [Cites] Curr Oncol Rep. 2007 Mar;9(2):147-51 [17288882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):51-8 [15093898.001]
  • [Cites] Acta Otorrinolaringol Esp. 2006 Oct;57(8):359-63 [17117693.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2214-23 [14601092.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):411-24 [15161440.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Feb;134(2):170-7 [18283160.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Otolaryngol Pol. 2006;60(5):729-36 [17263246.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Dec;131(6):973-6 [15577800.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Ai Zheng. 2004 Nov;23(11 Suppl):1542-5 [15566676.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):719-30 [17543999.001]
  • [Cites] J Int Med Res. 2009 Jan-Feb;37(1):189-97 [19215690.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):114-8 [7558807.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):328-32 [2802037.001]
  • [Cites] Rhinology. 1998 Mar;36(1):12-4 [9569435.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1206-12 [15923101.001]
  • [Cites] J Otolaryngol. 2005 Dec;34(6):379-83 [16343397.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):222-8 [17127030.001]
  • [Cites] Acta Oncol. 2001;40(1):19-23 [11321654.001]
  • [Cites] Otolaryngol Pol. 2008;62(1):37-43 [18637419.001]
  • [Cites] Ir J Med Sci. 1995 Apr-Jun;164(2):139-41 [7607840.001]
  • [Cites] Head Neck. 2006 Oct;28(10):867-73 [16823871.001]
  • [Cites] Head Neck. 2005 Jul;27(7):575-84 [15825201.001]
  • [Cites] Otolaryngol Pol. 2007;61(4):572-5 [18260254.001]
  • (PMID = 19795137.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobalt Radioisotopes; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 62
  •  go-up   go-down


24. Uchida D, Shirato H, Onimaru R, Endou H, Aoyama H, Tsuchiya K, Nishioka T, Homma A, Furuta Y, Fukuda S, Miyasaka K: Long-term results of ethmoid squamous cell or undifferentiated carcinoma treated with radiotherapy with or without surgery. Cancer J; 2005 Mar-Apr;11(2):152-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Ethmoidal malignant tumors, for which intensity-modulated radiotherapy is expected to improve outcome, consist of heterogeneous pathological types.
  • We investigated the long-term treatment outcome of squamous cell carcinoma and undifferentiated carcinoma of the ethmoid sinus.
  • Radiation dose varied from 50.4 Gy in 16 fractions (50.4 Gy/16 Fr) to 65 Gy in 26 fractions with or without stereotactic boost irradiation.
  • Eleven patients received chemotherapy consisting mainly of platinum-based compounds.
  • Visual acuity of a single eye was impaired in three patients and was lost in five patients as a result of tumor progression, but no patient had visual impairment or loss due to radiotherapy.
  • Prospective trials using advanced technology should be carefully compared with historical controls because pathological types can considerably influence the treatment results.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Ethmoid Sinus / pathology. Paranasal Sinus Neoplasms / radiotherapy. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969991.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hatta C, Ogasawara H, Okita J, Kubota A, Ishida M, Sakagami M: Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification. Auris Nasus Larynx; 2001 Jan;28(1):55-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification.
  • METHODS: Fifty-three patients with non-Hodgkin's malignant lymphoma (NHL) of the sinonasal tract were treated between 1981 and 1997.
  • The primary sites were the nasal cavity (67.8%), maxillary sinus (20.8%), ethmoidal sinus (9.4%), and frontal sinus (1.9%).
  • Based on the origin of the tumor cells, the authors classified NHL of the sinonasal tract into five groups with the REAL classification of Japan: diffuse large B-cell lymphoma (22.6%), peripheral T-cell lymphomas (15.1%), angiocentric lymphoma (35.9%), other lymphomas and unclassified types.
  • Of 53 patients, 39 (73.6%) received chemotherapy and radiotherapy, eight patients received chemotherapy alone, and four patients received radiotherapy alone.
  • The cumulative 5-year survival rates were 28.5% for all of the types, 55.0% for diffuse large B-cell lymphoma, 33.3% for peripheral T-cell lymphoma, and 19.7% for angiocentric lymphoma.
  • Results suggest that conventional combined treatment (CHOP chemotherapy+radiotherapy) is ineffective for NHL of the sinonasal tract, and especially so for NHL in the nasal cavity, NHL with tumor cells with positive T-cell markers, NHL further than Stage IIE and NHL with B symptoms.
  • CONCLUSION:. (1) In light of this ineffectiveness, new therapies must be developed to improve patient outcome instead of the conventional combined treatment;.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / classification. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11137364.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


26. Hanbali F, Tabrizi P, Lang FF, DeMonte F: Tumors of the skull base in children and adolescents. J Neurosurg; 2004 Feb;100(2 Suppl Pediatrics):169-78
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the majority of the available reports, the authors focus on the technical application of skull base approaches, but they contribute a paucity of information on the management of specific tumors, especially malignant skull base lesions.
  • The purposes of this report are to increase the collective experience with the treatment of these tumors and to identify successful management paradigms.
  • Surgery-related complications and outcomes were analyzed with regard to tumor type and surgical approach.
  • Benign lesions were discovered in 11 patients (46%) and malignant neoplasms in 13 (54%).
  • A gross-total resection was achieved in 23 procedures (77%) and a subtotal resection in five (17%); a biopsy procedure was performed in one case; and the disease process could not be accessed in one case.
  • In nine patients (38%) the tumor recurred after a mean duration of 23 months.
  • Sarcomas account for the majority of malignant tumors.
  • Treatment of skull base tumors in children and adolescents needs to be tailored to patient age, tumor location, and tumor type.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Diagnostic Imaging. Female. Humans. Infant. Male. Neurologic Examination. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / surgery. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Sarcoma / diagnosis. Sarcoma / secondary. Sarcoma / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14758945.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gupta S, Syed F, Murthy RK, Brar VS, Chalam KV: Sinonasal lymphoma masquerading as persistent blepharoconjunctivitis. Orbit; 2009;28(1):34-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal lymphoma, a rare nonepithelial malignant tumor often originates from the nose and paranasal sinuses.
  • Typically, these lymphomas present with symptoms of nasal obstruction, discharge, epistaxis and facial swelling.
  • The tumor was positively identified with immunoreactivity of biopsy specimen; Appropriate chemotherapy lead to successful remission of the disease.
  • [MeSH-major] Blepharitis / diagnosis. Conjunctivitis / diagnosis. Lymphoma / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Female. Humans. Prednisone / therapeutic use. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pinkeye.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19229743.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


28. Kumar S, Gupta AK, Yadav BS, Ghoshal S: Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study. Ear Nose Throat J; 2009 Dec;88(12):1269-72
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study.
  • We conducted a retrospective study to evaluate the clinicopathologic features and prognostic factors associated with primary sinonasal malignant melanoma.
  • The tumors were located in the nasal cavity in 7 patients and in a paranasal sinus in the other 3.
  • Medial maxillectomy was performed in 4 patients, wide local excision in 3, and endoscopic excision in 2; the remaining patient, who had presented with a liver metastasis, received chemotherapy and palliative local radiotherapy.
  • Based on the findings of our small study, we conclude that primary sinonasal malignant melanoma carries a generally poor prognosis despite aggressive treatment.
  • Other factors that appeared to be associated with a poor prognosis were (1) older age, (2) a primary tumor location in a paranasal sinus, (3) an advanced tumor stage, (4) an external approach to surgery, and (5) the absence of adjuvant radiotherapy.
  • [MeSH-major] Melanoma / pathology. Melanoma / surgery. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013681.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement